ACT-385781A PAH

Open-label study ACT-385781A in patients with pulmonary arterial hypertension

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1080221971

Enrollment

Registered

2012-12-03

Start date

2012-12-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary arterial hypertension (PAH)

Interventions

investigational material(s) Generic name etc : ACT-385781A INN of investigational material : epoprostenol Therapeutic category code : 219 Other cardiovascular agents Dosage and Administration for Inve

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with the following types of pulmonary arterial hypertension (PAH) belonging to Dana Point classification Group I: Idiopathic (IPAH), Heritable (HPAH), Drugs and toxins induced, or Associated (APAH) with Connective tissue diseases

Exclusion criteria

Exclusion criteria: Patients with respiratory and/or cardiovascular distress in need of emergency care, Known or suspicion of pulmonary veno-occlusive disease (PVOD), etc.

Design outcomes

Primary

Measure	Time frame
AE, Vital sign, Body weight and clinical laboratory test, etc.	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026